Blog/Private Equity
The top private equity firms in Singapore, ranked by their latest closed flagship fund, are Quadria Capital, Capital Square Partners, Dymon Asia Private Equity, ABC Impact and Growtheum Capital Partners. The ranked firms’ latest funds run from $379m to $1.07bn, while global firms run Asia funds of $5.3bn to $15.6bn with teams in the city.
For you, the choice is between local firms doing mid-market and growth deals across Southeast Asia and India, and global firms’ Singapore offices working on much larger pan-Asian deals.
Below we rank eight Singapore-headquartered firms, add Affirma Capital, and list four global firms with Singapore offices.
Singapore-headquartered firms are ranked by the size of their latest closed flagship private equity fund, as reported by the firm, its law firm or trade press, as of 20 November 2026. Global firms are listed separately because their funds cover the whole of Asia or the world. We leave out sovereign investors such as Temasek and GIC, which invest as owners and LPs. We also exclude Northstar and Crescent Point, now part of Ares, and Navis, which is headquartered in Kuala Lumpur.
| Rank | Firm | Latest flagship fund | Size | Closed |
|---|---|---|---|---|
| 1 | Quadria Capital | Fund III | $1.07bn | May 2025 |
| 2 | Capital Square Partners | CSP Fund II | About $700m | Jan 2023 |
| 3 | Dymon Asia Private Equity | Fund III | $650m | Sep 2022 |
| 4 | ABC Impact | Fund II | Over $600m | Apr 2025 |
| 5 | Growtheum Capital Partners | SEA Fund I | $567m | Aug 2023 |
| 6 | Novo Tellus Capital Partners | PE Fund 3 | $510m | Dec 2023 |
| 7 | Asia Partners | Asia Partners II | $474m | Jan 2024 |
| 8 | Tower Capital Asia | Tower Capital PE Fund I | $379m | Sep 2022 |
Fund sizes are in US dollars and include co-investment where a combined total was published, as for Quadria and Tower.
Quadria Capital closed Fund III at $1.07bn in May 2025, above its $800m target, including about $114m of co-investment. It invests only in healthcare across South and Southeast Asia, taking significant minority or majority stakes. Recent Fund III deals include Aragen Life Sciences, NephroPlus and Maxivision.
Capital Square Partners closed CSP Fund II at about $700m in January 2023, raised together with Basil Technology Partners. The fund also acquired existing portfolio assets as part of the close. It invests in technology services, healthcare, consumer and business services across Southeast Asia and India.
Dymon Asia Private Equity closed its third Southeast Asia fund at its $650m hard cap in September 2022, above a $550m target. It does management buyouts, growth deals and take-privates, with equity cheques of $15m to $50m. Its deals include the take-private of Singapore O&G, the purchase of Sembcorp’s biowaste unit and the carve-out of RAM Spreaders.
ABC Impact, part of Temasek Trust Asset Management, closed Fund II at over $600m in April 2025, about double its first fund. It invests in Asian companies in climate, inclusive finance, health and education, and food systems, with a focus on impact. Its LPs include the Asian Development Bank and Temasek.
Growtheum Capital Partners closed SEA Fund I at $567m in August 2023, below its $750m target. AVCJ called it the largest first-time private equity fund focused mainly on Southeast Asia. Its founder previously led GIC’s Southeast Asia direct private equity team. In December 2024 it invested $121m in Philippine cold-chain firm Mets Logistics.
Novo Tellus Capital Partners closed PE Fund 3 at its $510m hard cap in December 2023. It invests in technology and industrial supply chain businesses across the Indo-Pacific and reports over $1bn of assets under management. Its carve-out of TDConnex won the Singapore Venture and Private Capital Association’s 2025 private equity deal of the year.
Asia Partners closed its second fund at $474m in January 2024, up from $384m for Fund I, taking assets under management to $1.0bn. It writes growth cheques of $20m to $100m into Southeast Asian technology companies at the Series C and D stage.
Tower Capital Asia closed its first fund at $379m in September 2022, including $55m of co-investment, against a $300m target. It does mid-market buyouts and privatisations with a Singapore focus. In February 2026 it took a majority stake in V-Key, a digital identity and mobile security company.
Affirma Capital runs mid-market private equity across Korea, India, Southeast Asia, China, Africa and the Middle East from Singapore, and reports $4bn of assets under management. Its latest final close was Ascenta V, a Korea fund, at KRW543bn (about $473m) in October 2021. Ascenta VI reached a $370m first close in April 2024, so Affirma sits outside the ranking.
These firms run Asia or global funds and staff deal teams in Singapore:
Singapore took about $7bn of Southeast Asia’s roughly $14bn of private equity deal value in 2025, about half, according to Bain & Company. Regional deal value fell about 10% across 84 deals, and exit value fell 32%.
The Monetary Authority of Singapore reported 1,338 variable capital companies (VCCs, Singapore’s flexible fund structure) managed by licensed fund managers and banks at 1 April 2026. Temasek, one of the region’s largest LPs, reported a net portfolio value of S$518bn at 31 March 2026.
Match firms to your background and the deal size you want:
Our top investment banks in Singapore list covers the banks advising on deals in the city. Compare the market with our top private equity firms in India and New York rankings.
Among Singapore-headquartered firms, Quadria Capital has the largest recent flagship fund, after closing Fund III at $1.07bn in May 2025. Global firms run much larger Asia funds from Singapore, led by EQT’s $15.6bn BPEA Fund IX (April 2026) and KKR’s $15bn Asian Fund IV (April 2021).
Temasek and GIC are state-owned investors. They invest directly in companies and commit capital to private equity funds as LPs. Temasek reported a net portfolio value of S$518bn at 31 March 2026. Temasek also backs local managers, including as an LP in ABC Impact’s Fund II.
The ranked Singapore-headquartered private equity funds run from $379m to $1.07bn. Quadria’s Fund III is the largest at $1.07bn, and Tower Capital’s first fund closed at $379m. Global firms’ Asia funds run from TPG’s $5.3bn to EQT’s $15.6bn.
Singapore firms mostly invest across Southeast Asia and India. Quadria focuses on healthcare, Novo Tellus on technology supply chains, Asia Partners and Growtheum on growth companies, and Dymon Asia and Tower Capital on mid-market buyouts and take-privates.
The top private equity firms in Singapore are mid-market and growth investors led by Quadria, Capital Square and Dymon Asia, with latest funds of $379m to $1.07bn. Global firms such as EQT and KKR run far larger Asia funds from the city. Decide first whether you want local mid-market deals or large pan-Asian deals, then target firms on that side.
P.S. If you are building a target list of Asian funds, our Premium Resources include additional tools you might be interested in. For weekly finance updates and the latest financial reports, join the Private Equity Bros newsletter.
Join 80,000+ readers
One email a week: markets and finance news, the latest M&A deals and reports, investor biographies and deep dives.
Free forever. Unsubscribe anytime.